Back to Search Start Over

Cardiovascular risk stratification in hemodialysis patients in the era of highly sensitive troponins: should we choose between hs-troponin I and hs-troponin T?

Authors :
Stéphanie Badiou
François Maurice
Marion Morena
Gaelle Tachon
Hélène Leray-Moragues
Sebastien Deleuze
Lotfi Chalabi
Bouchra Badaoui
Nils Kuster
Laure Patrier
Jean-Paul Cristol
Bernard Canaud
Anne-Marie Dupuy
Anne-Sophie Bargnoux
Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)
Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Département de biochimie [Montpellier]
Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie
Centre hospitalier universitaire de Poitiers (CHU Poitiers)
Centre hémodialyse Languedoc Méditerranée (CHLM)
Centre hémodialyse Languedoc Méditerranée
CHU Henri Mondor
Association Installation à Domicile Epurations Rénales (AIDER)
Centre Hémodialyse Languedoc Méditerranée
CHLM
Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Source :
Clinical Chemistry and Laboratory Medicine, Clinical Chemistry and Laboratory Medicine, De Gruyter, 2016, 54 (4), pp.673-82. ⟨10.1515/cclm-2015-0071⟩
Publication Year :
2015

Abstract

Background New highly sensitive (hs) assays have challenged the interpretation of cardiac troponins (cTn). The present study was designed to evaluate simultaneously conventional cTnT and cTnI together with their corresponding highly sensitive determinations in stable hemodialysis (HD) patients. Ability of cTn to stratify HD patient risk was assessed. Methods A total of 224 stable HD patients was included in this observational study. cTnT and hs-cTnT were measured using Roche cTnT/hs-cTnT assays based on a Cobas e601® analyzer. cTnI and hs-cTnI were measured using Beckman AccuTnI/hs-TnI IUO assays on Access II system. Patients were followed up prospectively during 9 years. Relationship between cTn level and mortality was assessed through Cox survival analysis. Results The median cTnT and cTnI concentrations were 38.5 ng/L (IQR, 18.8-76) and 10 ng/L (IQR, 10-20), respectively. The median hs-cTnT and hs-cTnI concentrations were 62.5 ng/L (IQR, 38.8-96.3) and 13.9 ng/L (IQR, 8.4-23.6), respectively. The prevalence of values above the 99th percentile was significantly more marked with cTnT (85.3 and 97.8% for conventional and hs cTnT, respectively) than with cTnI (7.6 and 67.4% for conventional and hs cTnI, respectively). During the follow-up, 167 patients died, mainly from cardiac cause (n=77). The optimized cut-off values, determined by bootstrap method, predicting mortality were 38, 69, 20 and 11 ng/L for cTnT, hs-cTnT, cTnI and hs-cTnI, respectively. After full adjustment, elevated plasma concentrations of all troponin were significant predictors of mortality. Conclusions A large proportion of patients free of acute coronary syndrome (ACS) has hs-cTn I or T higher than the 99th percentile which could be seen as a limiting factor for ACS screening. However, all generation and type of troponin assays could be reliable indicators of prognosis risk in HD patients.

Details

ISSN :
14374331 and 14346621
Volume :
54
Issue :
4
Database :
OpenAIRE
Journal :
Clinical chemistry and laboratory medicine
Accession number :
edsair.doi.dedup.....cfe14befe8f3c6e7418754e53a965aba